SINK SIDE
NOTESSKIN-CARE DECISIONPRACTICAL CALL

U.S. ROUTINE CONTEXT · PRACTICAL CALL

Brighten dull, uneven-looking skin without repeated stinging

Choose an appearance-focused brightening routine that does not treat discomfort as an acceptable tradeoff.

NOTE 01

OUR SINK-SIDE CALL

The route we would take.

Reduce irritation before adding a brightening step

NOTE 02

Where the call changes.

CHOOSE DIFFERENTLY WHEN

  • Stinging is not a reliable signal of brightening performance.
  • Dull appearance can have causes a cosmetic comparison cannot diagnose.

WHAT WE ARE NOT CLAIMING

  • The full protocol, comparator, primary criteria, sample size and profile, dispersion, and complete report are often not public.

NOTE 03

HOW TO READ THIS NOTE

Evidence without theater.

This page makes an editorial call from documented context. It does not claim a product was owned, used, ranked, or independently tested. Manufacturer statements never become our results.

EVIDENCE TRAIL

What the sources carry — and what the desk decides.

The linked sources support product status, labeling, or professional boundaries. They do not prove the editorial winner and they do not stand in for an owned test.

EDITORIAL JUDGMENT

Reduce irritation before adding a brightening step

A reasoned course of action; not a product result measured by the source.
BOUNDARY OF THE CALL

Stinging is not a reliable signal of brightening performance.

The full protocol, comparator, primary criteria, sample size and profile, dispersion, and complete report are often not public.

Primary and professional sources in the record

  1. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?)U.S. Food and Drug Administration
  2. Cosmetics Labeling ClaimsU.S. Food and Drug Administration
  3. Summary of Cosmetics Labeling RequirementsU.S. Food and Drug Administration
  4. 21 CFR Part 701 — Cosmetic LabelingOffice of the Federal Register / eCFR
  5. Health Products Compliance GuidanceU.S. Federal Trade Commission
  6. 21 CFR Part 740 — Cosmetic Product Warning StatementsOffice of the Federal Register / eCFR
  7. FDA Adverse Event Monitoring System (AEMS)U.S. Food and Drug Administration
Data and test conditions still required
Product function and category

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Ingredient list for the current version

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Amount, contact time, and frequency

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Evidence for the specific claim

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Standardized photography conditions

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Tolerance protocol and stop criteria

Document against the current U.S. product version; keep missing or non-comparable information visibly open.

Trace a general claim to its evidence

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Assess general tolerance with stop rules

Define and retain the conditions, date, material, and outcome before presenting any owned observation.

Document color under standardized light

Define and retain the conditions, date, material, and outcome before presenting any owned observation.